Novo Nordisk eyes oral Wegovy as semaglutide generics loom
With injectable semaglutide set to face generic entry in India in March, Novo Nordisk indicates plans to expand its oral obesity portfolio while defending its premium positioning through brand, scale and advocacy
With injectable semaglutide set to face generic entry in India in March, Novo Nordisk indicates plans to expand its oral obesity portfolio while defending its premium positioning through brand, scale and advocacy
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
